10:16 AM EDT, 08/11/2025 (MT Newswires) -- PharmaTher Holdings ( PHRRF ) was at last look up 8%, having been up 22% earlier, after announcing Monday that the Food & Drug Administration has approved its ketamine product, Ketarx, for surgical pain management.

The FDA approval provides a strong foundation for expanding the development of ketamine across diverse treatment areas including mental health conditions like depression, neurological disorders such as Parkinson's disease and Amyotrophic Lateral Sclerosis, and the management of rare or chronic pain, a statement said.

"Today marks a new chapter for PharmaTher ( PHRRF )," said Chief Executive Fabio Chianelli. "With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global leader in ketamine-based pharmaceuticals."

PharmaTher ( PHRRF ) shares are up $0.03, to $0.53, on the Canadian Securities Exchange.

Price: 0.54, Change: +0.04, Percent Change: +8.00